Georgina V. Long

172.9k citations

684 papers · 34.4k indexed · 22 hit papers · h-index 85

Oncology top 0.01%
Molecular Biology top 0.1%
Immunology top 0.1%
Pulmonary and Respiratory Medicine top 0.2%
Cancer Research top 0.2%

Co-authors: Richard A. Scolyer Alexander M. Menzies Matteo S. Carlino Richard Kefford Antoni Ribas John F. Thompson James Larkin James S. Wilmott
Topics: Cancer Immunotherapy and Biomarkers (367 papers)Melanoma and MAPK Pathways (337 papers)CAR-T cell therapy research (264 papers)
Cited by: Oncology Immunology Molecular Biology
Journals: Nature Cell The Lancet
Partner nations: Australia United States France

In The Last Decade

Georgina V. Long

639 papers receiving 34.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

2017 1.4k citations Richard A. Scolyer, Georgina V. Long et al. profile →
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, Reinhard Dummer et al. profile →
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

2017 874 citations Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
Targeted agents and immunotherapies: optimizing outcomes in melanoma

2017 869 citations Jason J. Luke, Antoni Ribas et al. profile →
Antibacterial agents based on the cyclic d,l-α-peptide architecture

2001 805 citations Georgina V. Long et al. profile →
Immune checkpoint inhibitors in melanoma

2021 794 citations Matteo S. Carlino, Georgina V. Long et al. profile →
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 794 citations Georgina V. Long, Alexander M. Menzies et al. Journal of Clinical Oncology profile →
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

2018 655 citations Georgina V. Long, Serigne Lo et al. profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Alexander M. Menzies, Douglas B. Johnson et al. Annals of Oncology profile →
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

2011 507 citations James S. Wilmott, Georgina V. Long et al. Clinical Cancer Research profile →
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Michael A. Davies, Caroline Robert et al. profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
Resistance to PD1/PDL1 checkpoint inhibition

2016 429 citations Georgina V. Long, Richard A. Scolyer et al. profile →
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Tuba N. Gide, Camelia Quek et al. Clinical Cancer Research profile →
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

2014 382 citations Helen Rizos, Alexander M. Menzies et al. Clinical Cancer Research profile →
Cutaneous melanoma

2023 350 citations Georgina V. Long, Alexander M. Menzies et al. profile →
A scoping review of factors influencing the implementation of liquid biopsy for cancer care

2025 16 citations Georgina V. Long, Helen Rizos et al. profile →

Peers

Countries citing papers authored by Georgina V. Long

Since Specialization

Citations

This map shows the geographic impact of Georgina V. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georgina V. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georgina V. Long more than expected).

Fields of papers citing papers by Georgina V. Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georgina V. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georgina V. Long. The network helps show where Georgina V. Long may publish in the future.

Co-authorship network of co-authors of Georgina V. Long

This figure shows the co-authorship network connecting the top 25 collaborators of Georgina V. Long. A scholar is included among the top collaborators of Georgina V. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georgina V. Long. Georgina V. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma—A Discrete Choice Experiment 2023 ·Patient ·Ann Livingstone,Kirsten Howard,Alexander M. Menzies,Georgina V. Long,Martin R. Stockler,Rachael L. Morton	3
2	1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma 2023 ·Annals of Oncology ·Irene L. M. Reijers,Petros Dimitriadis,Alexander M. Menzies,Ellen Kapiteijn,Astrid A.M. van der Veldt,Karijn P.M. Suijkerbuijk,Geke A.P. Hospers,Winan J. van Houdt,Robyn P.M. Saw,Annegien Broeks,Sten Cornelissen,Lindsay G. Grijpink-Ongering,Thomas E. Pennington,Andrew J. Colebatch,B. van de Wiel,Richard A. Scolyer,Alexander C. J. van Akkooi,Georgina V. Long,Christian U. Blank	2
3	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach 2023 ·Journal of Translational Medicine ·(unknown),Tuba N. Gide,Nurudeen A. Adegoke,Camelia Quek,(unknown),Alison J. Potter,Ellis Patrick,Robyn P.M. Saw,John F. Thompson,Andrew J. Spillane,Kerwin F. Shannon,Matteo S. Carlino,Serigne Lo,Alexander M. Menzies,Inês Pires da Silva,Georgina V. Long,Richard A. Scolyer,James S. Wilmott	6
4	Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy 2023 ·The Journal of Clinical Endocrinology & Metabolism ·Linda Wu,Matteo S. Carlino,David A. Brown,Georgina V. Long,Roderick Clifton‐Bligh,(unknown),(unknown),Sarah C. Sasson,Alexander M. Menzies,Venessa Tsang,Jenny E. Gunton	7
5	Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. 2023 ·Journal of Clinical Oncology ·Jason J. Luke,Paolo A. Ascierto,Muhammad Adnan Khattak,Luis de la Cruz‐Merino,Michele Del Vecchio,Piotr Rutkowski,Francesco Spagnolo,Jacek Mackiewicz,Vanna Chiarion‐Sileni,John M. Kirkwood,Caroline Robert,Jean‐Jacques Grob,Federica De Galitiis,Dirk Schadendorf,Matteo S. Carlino,(unknown),Mizuho Fukunaga‐Kalabis,Clemens Krepler,Alexander M.M. Eggermont,Georgina V. Long	7
6	Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K). 2023 ·Journal of Clinical Oncology ·Georgina V. Long,John M. Kirkwood,Christoph Höeller,Jean‐Jacques Grob,Jeffrey S. Weber,Janis M. Taube,Peter Mohr,Alexander Christopher Jonathan Van Akkooi,Carmen Loquai,Caroline Dutriaux,Vanna Chiarion‐Sileni,Daniel J. Tenney,Sonia Dolfi,Hao Tang,Corey Ritchings,Maurice Lobo,Federico Campigotto,Wenjia Wang,Brian Gastman,Michele Del Vecchio	8
7	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. 2023 ·Journal of Clinical Oncology ·Irene L. M. Reijers,Alexander M. Menzies,Judith M. Versluis,Robyn P.M. Saw,Winan J. van Houdt,Ellen Kapiteijn,(unknown),Karijn P.M. Suijkerbuijk,Hanna Eriksson,Geke A.P. Hospers,W. Martin C. Klop,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Andrew J. Spillane,Richard A. Scolyer,Bart A. van de Wiel,Alexander Christopher Jonathan Van Akkooi,Georgina V. Long,Christian U. Blank	6
8	Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ·Journal of Clinical Oncology ·Adnan Khattak,Jeffrey S. Weber,Tarek Meniawy,Matthew H. Taylor,George Ansstas,Kevin B. Kim,Meredith McKean,Georgina V. Long,Ryan J. Sullivan,Mark B. Faries,Thuy Tran,(unknown),Theresa Medina,Jennifer Segar,Victoria Atkinson,Geoffrey T. Gibney,Jason J. Luke,Elizabeth I. Buchbinder,Robert Meehan,Matteo S. Carlino,(unknown)	50
9	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. 2023 ·Journal of Clinical Oncology ·Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,(unknown),(unknown),(unknown),Sonia Dolfi,Georgina V. Long	7
10	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos,Karen A. Autio,Talia Golan,Konstantin Dobrenkov,Elliot Chartash,(unknown),Richard Wnek,Georgina V. Long	46
11	bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays 2018 ·Bioinformatics ·Kevin Wang,Alexander M. Menzies,Inês Pires da Silva,James S. Wilmott,Yibing Yan,Matthew Wongchenko,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Garth Tarr,(unknown),Jean Yang	1
12	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment 2018 ·Clinical Cancer Research ·Jarem Edwards,James S. Wilmott,Jason Madore,Tuba N. Gide,Camelia Quek,Annie Tasker,Angela L. Ferguson,Jinbiao Chen,Rehana Hewavisenti,Peter Hersey,Thomas Gebhardt,Wolfgang Weninger,Warwick J. Britton,Robyn P.M. Saw,John F. Thompson,Alexander M. Menzies,Georgina V. Long,Richard A. Scolyer,Umaimainthan Palendira	317
13	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy 2018 ·Clinical Cancer Research ·Su Yin Lim,Jenny Lee,Tuba N. Gide,Alexander M. Menzies,Alexander Guminski,Matteo S. Carlino,Edmond J. Breen,Jean Yang,Shila Ghazanfar,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Helen Rizos	271
14	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume 2015 ·Molecular Cancer Therapeutics ·Nicholas Theodosakis,Matthew A. Held,(unknown),Katrina Meeth,Goran Micevic,Georgina V. Long,Richard A. Scolyer,David F. Stern,Marcus Bosenberg	29
15	PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials 2014 ·Pigment Cell & Melanoma Research ·Jason Madore,Ricardo E. Vilain,Alexander M. Menzies,Hojabr Kakavand,James S. Wilmott,Jessica Hyman,Jennifer H. Yearley,Richard Kefford,John F. Thompson,Georgina V. Long,Peter Hersey,Richard A. Scolyer	333
16	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) 2013 ·Clinical Cancer Research ·Katherine L. Nathanson,Anne‐Marie Martin,Bradley Wubbenhorst,Joel Greshock,Richard Letrero,Kurt D’Andrea,Steven O’Day,Jeffrey R. Infante,Gerald S. Falchook,Hendrik‐Tobias Arkenau,Michael Millward,Michael P. Brown,Anna C. Pavlick,Michael A. Davies,Bo Ma,Robert Gagnon,(unknown),Peter F. Lebowitz,Richard Kefford,Georgina V. Long	132
17	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
18	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma 2013 ·Molecular Cancer Therapeutics ·Matteo S. Carlino,Kavitha Gowrishankar,Catherine A.B. Saunders,Gulietta M. Pupo,(unknown),Xu Dong Zhang,Robyn P.M. Saw,Therese M. Becker,Richard Kefford,Georgina V. Long,Helen Rizos	61
19	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition 2012 ·Journal of Clinical Oncology ·Lisa Zimmer,Uwe Hillen,Elisabeth Livingstone,Mario E. Lacouture,Klaus J. Busam,Richard D. Carvajal,Friederike Egberts,Axel Hauschild,Mohammed Kashani–Sabet,Simone M. Goldinger,Reinhard Dummer,Georgina V. Long,Grant A. McArthur,André Scherag,Antje Sucker,Dirk Schadendorf	167
20	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanomabreakdown → 2011 ·Clinical Cancer Research ·James S. Wilmott,Georgina V. Long,Julie R. Howle,Lauren E. Haydu,Raghwa Sharma,John F. Thompson,Richard Kefford,Peter Hersey,Richard A. Scolyer	507

About Georgina V. Long

Georgina V. Long is a scholar working on Oncology, Immunology and Molecular Biology, having authored 684 papers that have together received 34.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (367 papers), Melanoma and MAPK Pathways (337 papers) and CAR-T cell therapy research (264 papers). The work is most often cited by research in Oncology (25.4k citations), Immunology (9.2k citations) and Molecular Biology (16.6k citations). Georgina V. Long has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Richard A. Scolyer, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Antoni Ribas, John F. Thompson, James Larkin, James S. Wilmott, Keith T. Flaherty and Lauren E. Haydu. Their work appears in journals such as Nature, Cell and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact